

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number Unassigned  
Filing Date 09/30/2005  
First Named Inventor Dominique BOUREL et al.  
Group Art Unit Unassigned  
Examiner Name Unassigned  
Attorney Docket Number 065691-0408

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A1	EP	0 481 790	A	WELLCOME FOUND	04/22/1992		
	A2	WO	97/28267	A	GRAY et al.	08/07/1997		
	A3	WO	99/58572	A	UNIV. CAMBRIDGE TECH	11/18/1999		
	A4	WO	01/77181	A	GLACET et al.	10/18/2001		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	DAVIES et al., "Expression of GnTIII in A Recombinant Anti-CD20 CHO Production Cell Line: Expression of Antibodies with altered Glycoforms Leads To An Increase in ADCC Through Higher Affinity of FcγRIIIa," Biotechnology and Bioengineering Combinatorial Chemistry, Vol. 74, No. 4, August 2001, pgs. 288-294.	
	A6	SHIELDS et al., "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIIIa and Antibody-Dependent Cellular Toxicity," Journal of Biological Chemistry, American Society of biological Chemists, Vol. 277, No. 30, July 26, 2002, pgs. 26733-26740.	
	A7	WRIGHT et al., "Effect of Glycosylation on Antibody Function: Implications For Genetic Engineering," Trends in Biotechnology, Elsevier Publications, Vol. 15, No. 1, 1997, pgs. 26-32.	

Examiner Signature

/Ilia Ouspenski/

Date Considered

11/28/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. P. 11/28/2008